GTS5:Turner syndrome: Difference between revisions

(View all pending changes)

[checked revision]

← Older edit Newer edit →

VisualWikitext

@@ Line 4: / Line 4: @@
 <span style="color:#0070C0">(''General Instructions – The focus of these pages is the clinically significant genetic alterations in each disease type, which is based on current knowledge within the WHO classification books and using resources such as PubMed for the latest information. If the same disease is described in multiple WHO classification books, the genetics-related information for that disease will be consolidated into a single main page that has this template (other pages would only contain a link to this main page). Use [https://www.genenames.org/ <u>HUGO-approved gene names and symbols</u>] (italicized when appropriate), [https://varnomen.hgvs.org/ HGVS-based nomenclature for variants], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples); to add (or move) a row or column in a table, click nearby within the table and select the > symbol that appears. Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see'' </span><u>''[[Author_Instructions]]''</u><span style="color:#0070C0"> ''and [[Frequently Asked Questions (FAQs)|<u>FAQs</u>]] as well as contact your [[Leadership|<u>Associate Editor</u>]] or [mailto:CCGA@cancergenomics.org <u>Technical Support</u>])''</span>
 ==Primary Author(s)*==
-Put your text here<span style="color:#0070C0"> (''<span class="blue-text">EXAMPLE:</span>'' Jane Smith, PhD) </span>
+Kathleen Bone, PhD, Medical College of Wisconsin
 ==WHO Classification of Disease==
-<span style="color:#0070C0">(''Instructions: This table’s content will be autogenerated.'')</span>
 {| class="wikitable"
 !Structure
@@ Line 12: / Line 11: @@
 |-
 |Book
-|
+|Genetic Tumor Syndromes (5th ed.)
 |-
 |Category
-|
+|DNA repair and genomic instability
 |-
 |Family
-|
+|Chromosomal and non-dysjunction (aneuploidy) syndromes
 |-
 |Type
-|
+|N/A
 |-
 |Subtype(s)
-|
+|Turner Syndrome
 |}
 ==Definition / Description of Disease==
-Put your text here <span style="color:#0070C0">(''Instructions: Include a brief general clinical description, diagnostic criteria, and differential diagnosis if applicable. Include disease context relative to other WHO classification categories, i.e. describe any organ-specific information pertinent to the genetic aspects of the disease across all applicable WHO classification books.'') </span>
+Turner Syndrome (TS) is a rare chromosomal disorder resulting from complete or partial loss of the second sex chromosome. The most common clinical manifestations include short stature, ovarian failure, primary or secondary amenorrhea associated with hypergonadotropic hypogonadism, congenital lymphedema of the hands and feet, Madelung deformity of the forearm and wrist, webbed neck, cardiac anomalies such as coarctation of the aorta, bicuspid aortic valves, mitral valve prolapse, hypertension, ischemic heart disease and arteriosclerosis, impaired glucose tolerance, thyroid disease and hearing loss.<ref name=":0">{{Cite journal|last=Gravholt|first=Claus H.|date=2005-11|title=Clinical practice in Turner syndrome|url=https://pubmed.ncbi.nlm.nih.gov/16929365|journal=Nature Clinical Practice. Endocrinology & Metabolism|volume=1|issue=1|pages=41–52|doi=10.1038/ncpendmet0024|issn=1745-8366|pmid=16929365}}</ref><ref>{{Cite journal|last=Bondy|first=Carolyn A.|last2=Bakalov|first2=Vladimir K.|date=2006-07|title=Investigation of cardiac status and bone mineral density in Turner syndrome|url=https://pubmed.ncbi.nlm.nih.gov/16624607|journal=Growth hormone & IGF research: official journal of the Growth Hormone Research Society and the International IGF Research Society|volume=16 Suppl A|pages=S103–108|doi=10.1016/j.ghir.2006.03.008|issn=1096-6374|pmid=16624607}}</ref><ref>{{Cite journal|last=Dhooge|first=Ingeborg J. M.|last2=De Vel|first2=E.|last3=Verhoye|first3=C.|last4=Lemmerling|first4=M.|last5=Vinck|first5=B.|date=2005-03|title=Otologic disease in turner syndrome|url=https://pubmed.ncbi.nlm.nih.gov/15793396|journal=Otology & Neurotology: Official Publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology|volume=26|issue=2|pages=145–150|doi=10.1097/00129492-200503000-00003|issn=1531-7129|pmid=15793396}}</ref><ref>{{Cite journal|last=Güngör|first=N.|last2=Böke|first2=B.|last3=Belgin|first3=E.|last4=Tunçbilek|first4=E.|date=2000-10|title=High frequency hearing loss in Ullrich-Turner syndrome|url=https://pubmed.ncbi.nlm.nih.gov/11039128|journal=European Journal of Pediatrics|volume=159|issue=10|pages=740–744|doi=10.1007/pl00008338|issn=0340-6199|pmid=11039128}}</ref><ref>{{Cite journal|last=Zinn|first=A. R.|last2=Tonk|first2=V. S.|last3=Chen|first3=Z.|last4=Flejter|first4=W. L.|last5=Gardner|first5=H. A.|last6=Guerra|first6=R.|last7=Kushner|first7=H.|last8=Schwartz|first8=S.|last9=Sybert|first9=V. P.|date=1998-12|title=Evidence for a Turner syndrome locus or loci at Xp11.2-p22.1|url=https://pubmed.ncbi.nlm.nih.gov/9837829|journal=American Journal of Human Genetics|volume=63|issue=6|pages=1757–1766|doi=10.1086/302152|issn=0002-9297|pmc=1377648|pmid=9837829}}</ref><ref>{{Cite journal|last=Sävendahl|first=L.|last2=Davenport|first2=M. L.|date=2000-10|title=Delayed diagnoses of Turner's syndrome: proposed guidelines for change|url=https://pubmed.ncbi.nlm.nih.gov/11035820|journal=The Journal of Pediatrics|volume=137|issue=4|pages=455–459|doi=10.1067/mpd.2000.107390|issn=0022-3476|pmid=11035820}}</ref> Despite considerable phenotypic variability, short stature and gonadal dysgenesis are the most consistent findings. While individuals with TS may experience impairments in nonverbal developmental skills, they generally have normal intellectual ability.<ref>{{Cite journal|last=Kesler|first=Shelli R.|date=2007-07|title=Turner syndrome|url=https://pubmed.ncbi.nlm.nih.gov/17562588|journal=Child and Adolescent Psychiatric Clinics of North America|volume=16|issue=3|pages=709–722|doi=10.1016/j.chc.2007.02.004|issn=1056-4993|pmc=2023872|pmid=17562588}}</ref> Turner syndrome should be suspected prenatally when a prenatal ultrasound reveals fetal hydrops, cystic hygroma, or cardiac defects. Approximately 50% of TS patients have monosomy X (45,X), while the remaining 50% exhibit various structural abnormalities of the X chromosome or mosaicism with a normal female or normal male cell line.
+[[File:45,X.png|center|thumb|G-banded chromosome analysis of a PHA-stimulated peripheral blood specimen from a patient with Turner Syndrome and a 45,X karyotype; Courtesy of Wisconsin Diagnostics Laboratories]]
+<br />
+[[File:Ring(X).tif|center|thumb|G-banded chromosome analysis of a PHA-stimulated peripheral blood specimen from a patient with variant Turner syndrome and a karyotype of 46,X,r(X)(p21q22)/45,X; Courtesy of Wisconsin Diagnostics Laboratories]]
+In individuals with mosaic TS and Y chromosomal material, external genitalia may vary from normal male to ambiguous to female with TS characteristics. The Y chromosome, if present, may also be structurally abnormal. A patient with TS showing evidence of virilization is more likely to be mosaic for a Y-containing cell line, which increases the risk for gonadoblastoma.<ref name=":0" /><ref name=":1">{{Cite journal|last=Gravholt|first=Claus H.|last2=Andersen|first2=Niels H.|last3=Christin-Maitre|first3=Sophie|last4=Davis|first4=Shanlee M.|last5=Duijnhouwer|first5=Anthonie|last6=Gawlik|first6=Aneta|last7=Maciel-Guerra|first7=Andrea T.|last8=Gutmark-Little|first8=Iris|last9=Fleischer|first9=Kathrin|date=2024-06-05|title=Clinical practice guidelines for the care of girls and women with Turner syndrome|url=https://pubmed.ncbi.nlm.nih.gov/38748847|journal=European Journal of Endocrinology|volume=190|issue=6|pages=G53–G151|doi=10.1093/ejendo/lvae050|issn=1479-683X|pmid=38748847}}</ref> Molecular screening for Y chromosomal material is recommended in such cases.
 ==Synonyms / Terminology==
-Put your text here <span style="color:#0070C0">(''Instructions: Include currently used terms and major historical ones, adding “(historical)” after the latter.'') </span>
+,X Syndrome, Monosomy X, Variant Turner Syndrome, Mosaic Turner Syndrome, Congenital Ovarian Hypoplasia Syndrome (historical), Ullrich-Turner Syndrome (historical), Bonnevie-Ullrich syndrome (historical), 45,XO (historical, not recommended)
 ==Epidemiology / Prevalence==
-Put your text here
+TS and its variants occur in approximately 1 in 2000 to 1 in 2500 live-born females.<ref>{{Cite journal|last=Cui|first=Xiaoxiao|last2=Cui|first2=Yazhou|last3=Shi|first3=Liang|last4=Luan|first4=Jing|last5=Zhou|first5=Xiaoyan|last6=Han|first6=Jinxiang|date=2018-11|title=A basic understanding of Turner syndrome: Incidence, complications, diagnosis, and treatment|url=https://pubmed.ncbi.nlm.nih.gov/30560013|journal=Intractable & Rare Diseases Research|volume=7|issue=4|pages=223–228|doi=10.5582/irdr.2017.01056|issn=2186-3644|pmc=6290843|pmid=30560013}}</ref><ref>{{Cite journal|last=Nielsen|first=J.|last2=Wohlert|first2=M.|date=1991-05|title=Chromosome abnormalities found among 34,910 newborn children: results from a 13-year incidence study in Arhus, Denmark|url=https://pubmed.ncbi.nlm.nih.gov/2037286|journal=Human Genetics|volume=87|issue=1|pages=81–83|doi=10.1007/BF01213097|issn=0340-6717|pmid=2037286}}</ref> However, TS is among the most common chromosomal disorders, affecting 1–2% of conceptions, with approximately 99% of affected pregnancies resulting in pregnancy loss.<ref>{{Cite journal|last=Urbach|first=Achia|last2=Benvenisty|first2=Nissim|date=2009|title=Studying early lethality of 45,XO (Turner's syndrome) embryos using human embryonic stem cells|url=https://pubmed.ncbi.nlm.nih.gov/19137066|journal=PloS One|volume=4|issue=1|pages=e4175|doi=10.1371/journal.pone.0004175|issn=1932-6203|pmc=2613558|pmid=19137066}}</ref> The true prevalence of TS is difficult to ascertain, as many individuals remain undiagnosed or are only diagnosed later in adulthood.<ref>{{Cite journal|last=Gunther|first=Daniel F.|last2=Eugster|first2=Erica|last3=Zagar|first3=Anthony J.|last4=Bryant|first4=Constance G.|last5=Davenport|first5=Marsha L.|last6=Quigley|first6=Charmian A.|date=2004-09|title=Ascertainment bias in Turner syndrome: new insights from girls who were diagnosed incidentally in prenatal life|url=https://pubmed.ncbi.nlm.nih.gov/15342833|journal=Pediatrics|volume=114|issue=3|pages=640–644|doi=10.1542/peds.2003-1122-L|issn=1098-4275|pmid=15342833}}</ref>
 ==Genetic Abnormalities: Germline==
-Put your text here and fill in the table <span style="color:#0070C0">(''Instruction: Can include references in the table. Do not delete table. If multiple causes of the syndrome, include relative prevalence of genetic contributions to that syndrome. In the notes, include additional details about most common mutations including founder mutations, mechanisms of molecular pathogenesis, alteration-specific prognosis and any other important genetic-related information with key references.'')</span>
 {| class="wikitable sortable"
 |-
@@ Line 42: / Line 46: @@
 |'''Notes'''
 |-
-|<span class="blue-text">EXAMPLE:</span> BRCA1||<span class="blue-text">EXAMPLE:</span> Many||<span class="blue-text">EXAMPLE:</span> Multiple variant types leading to loss of function||
+|''SHOX''
-|
+|Whole or partial X chromosome loss encompassing gene
-|-
+|Haploinsufficiency
-|<span class="blue-text">EXAMPLE:</span> Gene X
+|''De novo'', complete penetrance, complete expressivity
-|<span class="blue-text">EXAMPLE:</span> List the specific mutation
+|The ''short stature homeobox'' (''SHOX'') gene belongs to the paired homeobox family and is located in the pseudoautosomal region 1 (PAR1) on the short arms of the X (Xp22.3) and Y (Yp11.3) chromosomes.<ref>{{Cite journal|last=Rao|first=E.|last2=Weiss|first2=B.|last3=Fukami|first3=M.|last4=Rump|first4=A.|last5=Niesler|first5=B.|last6=Mertz|first6=A.|last7=Muroya|first7=K.|last8=Binder|first8=G.|last9=Kirsch|first9=S.|date=1997-05|title=Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome|url=https://pubmed.ncbi.nlm.nih.gov/9140395|journal=Nature Genetics|volume=16|issue=1|pages=54–63|doi=10.1038/ng0597-54|issn=1061-4036|pmid=9140395}}</ref> It plays a crucial role in skeletal development, particularly in the growth plates of bones, where it regulates the proliferation and differentiation of chondrocytes, the cells responsible for cartilage formation. ''SHOX'' is vital for normal bone growth and stature, and pathogenic variants or deletions in this gene are associated with TS and other syndromes, including Leri-Weill dyschondrosteosis, and idiopathic short stature.<ref name=":2">{{Cite journal|last=Binder|first=Gerhard|date=2011-02|title=Short stature due to SHOX deficiency: genotype, phenotype, and therapy|url=https://pubmed.ncbi.nlm.nih.gov/21325865|journal=Hormone Research in Paediatrics|volume=75|issue=2|pages=81–89|doi=10.1159/000324105|issn=1663-2826|pmid=21325865}}</ref> Both males and females typically have two copies of the ''SHOX'' gene, as it escapes X chromosome inactivation.<ref name=":2" /><ref>{{Cite journal|last=Berletch|first=Joel B.|last2=Yang|first2=Fan|last3=Xu|first3=Jun|last4=Carrel|first4=Laura|last5=Disteche|first5=Christine M.|date=2011-08|title=Genes that escape from X inactivation|url=https://pubmed.ncbi.nlm.nih.gov/21614513|journal=Human Genetics|volume=130|issue=2|pages=237–245|doi=10.1007/s00439-011-1011-z|issn=1432-1203|pmc=3136209|pmid=21614513}}</ref>
-|
-|
-|
 |}
 ==Genetic Abnormalities: Somatic==
-Put your text here and fill in the table <span style="color:#0070C0">(''Instruction: Describe significant second hit mutations, or somatic variants that present as a germline syndrome. Can include references in the table. Do not delete table. In the notes, include details about most common mutations, mechanisms of molecular pathogenesis, alteration-specific prognosis and any other important genetic-related information with key references.'') </span>
+N/A
 {| class="wikitable sortable"
 |-
@@ Line 61: / Line 62: @@
 |'''Notes'''
 |-
-|<span class="blue-text">EXAMPLE:</span> BRCA
+|N/A
-|<span class="blue-text">EXAMPLE:</span> Biallelic inactivation variants
+|N/A
-|<span class="blue-text">EXAMPLE:</span> Second hit mutation can occur as copy neutral LOH, inactivating mutation, deletion, promoter hypermethylation, or a structural abnormality disrupting the gene.
+|N/A
-|
+|N/A
-|
+|N/A
-|-
-|<span class="blue-text">EXAMPLE:</span> BRCA
-|<span class="blue-text">EXAMPLE:</span> Gain
-|<span class="blue-text">EXAMPLE:</span>After exposure to certain therapies (e.g. PARP inhibitors), a second mutation may restore gene function as a resistance mechanism.
-|
-|
 |}
 ==Genes and Main Pathways Involved==
@@ Line 92: / Line 87: @@
 |}
 ==Genetic Diagnostic Testing Methods==
-Put your text here
+TS can be diagnosed prenatally through chorionic villus sampling (CVS) or amniocentesis, followed by G-banded chromosome analysis or karyotyping. Postnatal confirmation requires chromosome analysis of a phytohemagglutinin (PHA)-stimulated peripheral blood (PB) specimen. In cases of mosaicism, the karyotype may appear normal, so additional diagnostic methods may be necessary.
+If TS is strongly suspected, a fluorescence in situ hybridization (FISH) study using an X chromosome centromere probe may be performed alongside karyotyping. Furthermore, if clinical suspicion remains high despite normal results from chromosome analysis and FISH, a chromosome analysis of a skin fibroblast culture may be indicated.
+In patients with TS who exhibit signs of virilization, the presence of Y chromosomal material is a significant concern, as it increases the risk for the development of gonadoblastoma, a type of germ cell tumor.<ref name=":1" /> To detect Y chromosomal material, polymerase chain reaction (PCR) is a sensitive and specific molecular method used for screening. PCR involves amplifying DNA sequences specific to the Y chromosome, such as SRY (sex-determining region Y), TSPY (testis-specific protein Y-encoded), or other Y-specific markers.<ref>{{Cite journal|last=Mendes|first=J. R.|last2=Strufaldi|first2=M. W.|last3=Delcelo|first3=R.|last4=Moisés|first4=R. C.|last5=Vieira|first5=J. G.|last6=Kasamatsu|first6=T. S.|last7=Galera|first7=M. F.|last8=Andrade|first8=J. A.|last9=Verreschi|first9=I. T.|date=1999-01|title=Y-chromosome identification by PCR and gonadal histopathology in Turner's syndrome without overt Y-mosaicism|url=https://pubmed.ncbi.nlm.nih.gov/10341852|journal=Clinical Endocrinology|volume=50|issue=1|pages=19–26|doi=10.1046/j.1365-2265.1999.00607.x|issn=0300-0664|pmid=10341852}}</ref> This technique can identify even low levels of mosaicism, which might not be detectable by conventional karyotyping or FISH. When Y chromosomal material is confirmed, preventive measures, such as gonadectomy, are typically recommended to reduce the risk of malignancy.<ref name=":1" /> PCR is particularly valuable in cases where clinical findings and standard cytogenetic testing are inconclusive but there is strong clinical suspicion of Y chromosomal mosaicism. This molecular approach complements cytogenetic methods, providing a comprehensive evaluation for patients with TS and virilization.
 ==Additional Information==
 Put your text here